Crizotinib: New Standard for ALK+ Myofibroblastic Tumor Crizotinib: New Standard for ALK+ Myofibroblastic Tumor

With 100% disease control rates in patients with ALK+ inflammatory myofibroblastic tumor -- a very rare type of soft tissue sarcoma -- crizotinib should be the standard of care, say experts.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news